Filing Flows › Health Care › Atara Biotherapeutics (ATRA)
Atara Biotherapeutics (ATRA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Atara Biotherapeutics (ATRA) Q2 2026 earnings results →
Q2 2026 Revenue down 96% year over year to $630K · 767¢ of every $1 of revenue lost · operating margin -749.2%
Atara Biotherapeutics made $630K in Q2 2026 (-96% Y/Y). Operating margin -749.2%, net loss $4.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $630K in Q2 2026, down 96% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $4.7M, an operating margin of -749.2%. Total costs fell 63% while revenue fell 96%. The quarter ended with a net loss of $4.8M, wider than the previous quarter's $4.1M loss.
Operating cash flow was −$3.3M. Non-cash charges added back $14K of depreciation and amortization and $394K of share-based compensation. Working capital and other items added $1.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $630K | -96% | -749.2% | −$4.8M | −$3.3M |
| Q1 2026 | 10-Q | May 12, 2026 | $516K | -100% | -652.9% | −$4.1M | −$3.1M |
| Q4 2025 | 10-K | Mar 16, 2026 | $1.6M | -95% | -160.7% | −$3.4M | −$5.7M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $3.5M | -91% | -103.5% | −$4.3M | −$9.8M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $17.6M | -39% | 18.2% | $2.4M | −$7.3M |
| Q1 2025 | 10-Q | May 15, 2025 | $98.1M | +259% | 39.5% | $38.0M | −$28.1M |
| Q4 2024 | 10-K | Mar 7, 2025 | $32.8M | +670% | -37.3% | −$12.7M | −$24.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Atara Biotherapeutics
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn .
In its own words, from its 8-K, filed Aug 12, 2026.
Atara Biotherapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -96% against the peers' median +11%. Operating margin: -749.2% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Q2 2026 | $630K | -96% | -749.2% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Atara Biotherapeutics 10-Q on SEC EDGAR · CIK 1604464 · Biological Products, (No Diagnostic Substances)
13F: who owns ATRA and who is buying
More on ATRA
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results